Creatinine News and Research

RSS

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.

27 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

FDA clears Mitsubishi's PATHFAST cardiac Troponin I diagnostic test

Mitsubishi Chemical Medience Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) premarketing notification clearance to the PATHFAST cTnI-II diagnostic test, clearing the way for its sale in the United States.

14 Jun 2011

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomics Analysis Reveals Elevation of 3-Indoxyl Sulfate in Plasma and Brain during Chemically-induced Acute Kidney Injury in Mice: Investigation of Nicotinic Acid Receptor Agonists", in Toxicology and Applied Pharmacology.

9 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Results from the DACO-016 trial of Dacogen (decitabine) in acute myeloid leukemia (AML) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Takeda Global Research & Development Center, Inc. U.S., today announced results from three phase 3 studies of the investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone.

24 May 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

Patients with chronic heart failure can benefit from telemonitoring

Two trials presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology, will help to define the precise populations of patients with chronic heart failure in whom telemedical management delivers benefits.

23 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

Older heart-transplant recipients more likely to be alive if operated at high-volume centers

Older, sicker heart-transplant recipients are significantly more likely to be alive a year after their operations if they have their transplants at hospitals that do a large number of them annually new Johns Hopkins research suggests. These patients fare less well at low-volume centers, the research shows.

10 May 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011

Desirudin more effective for VTE prevention in patients with renal impairment

Desirudin reduced major venous thromboembolism and post-operative bleeding compared with the standard of care, enoxaparin, in patients with poor kidney function undergoing orthopedic surgery, according to a poster presented at the Arteriosclerosis, Thrombosis and Vascular Biology meeting.

3 May 2011

Elderly individuals with CKD more likely to suffer from heart disease

Chronic kidney disease is common and linked with heart disease in the very elderly, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

22 Apr 2011

New biomarker-based test more effective for early acute kidney injury detection

A new biomarker-based diagnostic test is more effective than the current best practice for early detection of adverse outcomes after acute kidney injury, which can be fatal for an estimated 50 percent of the critically ill patients who get the condition.

19 Apr 2011

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that EDARBI, an angiotensin II receptor blocker approved for the treatment of hypertension, or high blood pressure, is now available by prescription for adults in U.S. pharmacies.

15 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC Systems Inc., a company focused on innovative medical device technologies, announced that final results from the REMEDIAL II investigator-sponsored clinical trial of RenalGuard in Italy were presented today.

5 Apr 2011

Creatinine News and Research

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

FDA approves NULOJIX

FDA clears Mitsubishi's PATHFAST cardiac Troponin I diagnostic test

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Patients with chronic heart failure can benefit from telemonitoring

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Older heart-transplant recipients more likely to be alive if operated at high-volume centers

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Desirudin more effective for VTE prevention in patients with renal impairment

Elderly individuals with CKD more likely to suffer from heart disease

New biomarker-based test more effective for early acute kidney injury detection

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News